Tokyo, Nov. 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059699) titled 'Observational Study on the Efficacy and Adverse Effects of Foslevodopa Foscarbidopa Continuous Subcutaneous Infusion (FOCS)' on Nov. 8.
Study Type:
Observational
Primary Sponsor:
Institute - National Center of Neurology and Psychiatry
Condition:
Condition - Parkinson's disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This retrospective chart review included patients who received Foslevodopa Foscarbidopa Continuous Subcutaneous Infusion (FOCS) at our hospital, with the objective of identifying and characterizing issues arising during the clinical management of FOCS.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - All patients treated with FOCS at the National Center Hospital, National Center of Neurology and Psychiatry, were included.
Key exclusion criteria - When the patient or their family declined to participate in this study.
Target Size - 100
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2023 Year 07 Month 19 Day
Date of IRB - 2023 Year 07 Month 21 Day
Anticipated trial start date - 2025 Year 10 Month 07 Day
Last follow-up date - 2028 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067841
Disclaimer: Curated by HT Syndication.
